证券代码：300529 证券简称：健帆生物 公告编号：2023-095 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2023 年 6 月 19 日 召开了 2023 年第一次临时股东大会，审议通过了《关于修订＜公司章程＞的议 案》，鉴于公司回购注销 2021 年限制性股票激励计划未能解禁的第一类限制性股 票 15.60 万股，使得公司总股本相应减少 15.60 万股，公司总股本从 80771.1312 万股减少至 80755.5312 万股，公司注册资本由 80771.1312 万元减少至 80755.5312 万元。 近日，公司完成了工商登记变更及《公司章程》备案，并取得了珠海市市场 监督管理局换发的《营业执照》。具体相关信息如下： 一、基本情况 8、经营范围：许可项目：第三类医疗器械生产；第三类医疗器械经营；第 三类医疗器械租赁；第二类医疗器械生产；食品销售；第二类增值电信业务；医 疗器械互联网信息服 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2023-094 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 关于公司两项新产品取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"健帆生物"或"公司"）于近 日收到国家药品监督管理局颁发的两项《医疗器械注册证》，公司的新产品一次 性使用血液灌流器、连续性肾脏替代治疗用管路分别取得医疗器械注册证。其中， 一次性使用血液灌流器（pHA 系列）是国内首个获批的可以同时清除终末期肾 病（ESRD）患者体内蛋白结合毒素和中大分子毒素的血液灌流器产品，连续性 肾脏替代治疗用管路是临床进行连续性血液净化（CRRT）治疗中必不可少的一 次性使用医疗器械耗材。具体情况如下： | 序 | 产品名称 | 注册证 | 分类 | 注册证有 | 型号、规格 | 适用范围 | 注册人 | | --- | --- | --- | --- | --- | --- | --- | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次完成回购注销的限制性股票共计 156,000 股，占回购前健帆生物科 技集团股份有限公司（以下简称"公司"）总股本的 807,711,312 股的 0.0193%， 涉及激励对象 5 人。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司已于 2023 年 8 月 10 日办理完成上述限制性股票的回购注销手续。 证券代码：300529 证券简称：健帆生物 公告编号：2023-093 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于部分限制性股票回购注销完成暨不调整健帆转债转股 价格的公告 3、本次限制性股票回购注销完成后，公司总股本由 807,711,312 股变更为 807,555,312 股。 4、因公司本次股份变动数量占公司总股本的比例很小，经计算，本次限制 性股票回购注销完成后，"健帆转债"的转股价格不变，仍为 61.72 元/股。 一、本激励计划简述 1、2021 年 2 月 4 日公司召开第四届董事会第十次会议，审议通过了《关于 公司<202 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥572,557,659.76, a decrease of 17.90% compared to ¥697,355,409.35 in the same period last year[6] - Net profit attributable to shareholders for Q1 2023 was ¥196,529,798.71, down 41.37% from ¥335,207,463.10 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥189,734,884.06, reflecting a 41.18% decline compared to ¥322,594,519.17 in the previous year[6] - Basic earnings per share for Q1 2023 were ¥0.25, a decrease of 40.48% from ¥0.42 in the same period last year[6] - Diluted earnings per share were ¥0.24, down 41.46% from ¥0.41 year-on-year[6] - The total profit for the current period was ¥231,678,904.69, down 41.0% from ¥393,157,424.42 in the previous period[17] - The net profit for the period was 195,250,686.39 CNY, down 41.61% from 334,390,326.17 CNY in the previous year, highlighting challenges in revenue generation[28] Cash Flow and Liquidity - The net cash flow from operating activities increased by 86.83% to ¥239,264,872.20, up from ¥128,066,902.76 in the same quarter last year[6] - The company's cash and cash equivalents increased to ¥3,084,030,612.75 from ¥2,558,755,452.52 at the beginning of the year[9] - Cash received from tax refunds rose significantly by 453.98% to ¥1,390,619.07, mainly due to an increase in software tax refunds[31] - The company reported a 259.56% increase in net cash and cash equivalents, totaling ¥535,713,372.63, attributed to new bank loans and reduced payments for construction and procurement[31] - Cash inflow from financing activities surged by 9396.94% to ¥329,199,971.04, driven by an increase in bank loans to optimize the capital structure[31] Operating Costs and Expenses - Total operating costs increased to ¥350,485,573.54, up 11.5% from ¥314,319,565.99 in the previous period[15] - Research and development expenses increased to ¥54,023,867.54, up 32.3% from ¥40,771,649.13 in the previous period[15] - Sales expenses rose to ¥156,935,831.02, an increase of 26.1% from ¥124,425,157.36 in the previous period[15] - The company reported a financial expense of -¥8,708,659.80, compared to a financial income of ¥957,753.62 in the previous period[15] - The company experienced a 1009.28% increase in financial expenses, resulting in a loss of -8,708,659.80 CNY, primarily due to increased interest income from deposits[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 64,574, with the largest shareholder holding 43.97% of the shares[33] - The largest shareholder, Dong Fan, holds 355,131,867 shares, representing 43.97% of the total shares[33] - The total number of restricted shares held by major shareholders at the end of the period was approximately 292.79 million shares[36] Challenges and Strategic Focus - The company faced challenges due to rising production costs and a higher sales proportion of blood purification equipment, leading to a decline in gross margin[39] - R&D and sales expenses increased year-on-year, contributing to the significant drop in net profit[39] - The company continues to invest in R&D and market promotion to support future growth[39]

Financial Performance - The company's total revenue for Q1 was approximately CNY 697.36 million, with a peak in Q2 at CNY 856.93 million, followed by a decline to CNY 471.42 million in Q3 and CNY 465.74 million in Q4[1]. - Net profit attributable to shareholders for Q1 was CNY 335.21 million, peaking in Q2 at CNY 412.95 million, but dropping significantly to CNY 16.09 million in Q4[1]. - The company's operating revenue for 2022 was ¥2,491,439,432.10, a decrease of 6.88% compared to the previous year[17]. - The net profit attributable to shareholders for 2022 was ¥889,537,704.85, reflecting a decline of 25.67% year-over-year[17]. - The net cash flow from operating activities for 2022 was ¥883,800,425.82, a decrease of 29.26% compared to 2021[17]. - In 2022, the company achieved a revenue of CNY 2.491 billion, a decrease of 6.88% year-on-year, and a net profit of CNY 890 million, down 25.67% year-on-year[28]. - The company reported a diluted earnings per share of CNY 1.1013 for the year[54]. - The company's total revenue for 2022 was approximately ¥2.49 billion, a decrease of 6.88% compared to ¥2.68 billion in 2021[135]. - The company reported a significant increase in blood purification equipment revenue, which rose by 163.18% to approximately ¥197.59 million[135]. - The gross profit margin for the medical device manufacturing sector was 82.70%, reflecting a decrease of 2.40% compared to the previous year[165]. Market Potential and Product Development - The market potential for blood perfusion treatment is estimated to exceed CNY 10 billion, with an annual market capacity of approximately 2.4 to 4 million devices based on 600,000 to 800,000 new cases of liver failure each year in China[8]. - The Double Plasma Molecular Adsorption System (DPMAS) is a new artificial liver treatment model that combines two products for enhanced blood purification, which has been included in several clinical guidelines[8]. - The company is actively participating in the "Voyage" project aimed at improving clinical practices in liver failure treatment through evidence-based training and standard operating procedures[13]. - The company is focusing on expanding its market through innovative treatment technologies and strategic partnerships in critical care areas[8]. - The company is actively exploring new product development, including DNA immunoadsorption columns and endotoxin adsorption columns, leveraging its advantages in ligand technology[28]. - The company aims to enhance its core competitiveness through the introduction of new products and technologies, including disposable blood/plasma adsorption products and continuous blood purification devices[180]. Research and Development - The company has initiated over 10 overseas clinical studies and published over 30 research papers in top international journals, promoting blood perfusion technology[14]. - The company's R&D investment reached ¥253.91 million, an increase of 46.12% year-on-year, accounting for 10.19% of total revenue[115]. - The company has a total of 306 authorized patents, including 59 invention patents, with 41 patents granted in 2022 alone[115]. - The company has conducted extensive training for over 100,000 medical staff nationwide, increasing awareness of its DPMAS artificial liver technology[125]. - The company's R&D team has grown to over 600 members, including 6 PhDs and more than 180 master's degree holders[115]. Sales and Market Expansion - The company has achieved product sales in 86 countries and has been included in the medical insurance directories of 11 countries, indicating successful market expansion[14]. - The company has established partnerships with regional core hospitals to create benchmark centers for blood purification technology and has published expert consensus on artificial liver devices[29]. - The company has expanded its renal product coverage to over 6,000 secondary and higher-level hospitals across China, focusing on chronic disease management and standardized treatment[92]. - The company has established a customer service center and a 24-hour hotline to enhance customer support and brand image[87]. - Jafron plans to expand its market presence in Southeast Asia, targeting a 30% growth in that region by 2024[39]. Operational Efficiency and Quality Control - The company has implemented automation in its main production processes and applied AI+ visual inspection technology to improve product quality[30]. - The company has established a quality management system since 2005, achieving ISO13485 certification and being recognized as a Class A medical device manufacturer in Guangdong Province for eleven consecutive years[89]. - The blood perfusion products are subject to strict quality control, with over 300 process documents and nearly 200 quality control documents in place[83]. - The company maintains a safety stock of approximately two months to meet market demand effectively[83]. Financial Management and Investments - The company has invested CNY 310 million in the Zhuhai Jian Shu New Materials Technology Co., Ltd. project, which focuses on automated production lines for raw material resins[30]. - The company has committed to donating to the "Artificial Liver Special Fund" for three consecutive years, supporting research in severe liver disease treatment[125]. - The company has faced challenges in international market sales, attributed to a significant decrease in critical illness patients and difficulties in promotional activities abroad[155].

证券代码：300529 证券简称：健帆生物 公告编号：2023-031 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于举办 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1 • 会议召开时间：2023 年 4 月 6 日（星期四）15:00-16:30 • 会议召开方式：网络互动方式 • 会议召开地点：价值在线（www.ir-online.cn） • 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 4 月 6 日 前 访 问 网 址 https://eseb.cn/13oYOLwIkik 或扫描下方小程序码，点击"进入会议"进行会 前提问，公司将通过本次业绩说明会上，在信息披露允许范围内就投资 者普遍关注的问题进行回答。 会议召开地点：价值在线（www.ir-online.cn） 健帆生物科技集团股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日 在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便 于广大投资者更加 ...

编号：2019-001 证券代码：300529 证券简称：健帆生物 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|------------------------|---------------------------------| | | | | | 投资者关系活动类 | ■ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 中银基金 | 王方舟 | | 员姓名 | 安信基金 | 徐衍鹏 | | | 浦银安盛 | 陈蔚丰 | | | 国寿安保 | 刘志军 | | | 东吴基金 | 毛可君 | | | 兴全基金 | 邱晓旭 | | | 上海彤源投资 | 庄琰 | | | 从容投资 | 罗凌 | | | 光大资管 | 曾炳祥 | | | 上海趣时资产 | 罗会礼 | | | 华泰资管 | 俞天甲 | | | 上海盛宇投资 | 张亚辉 | | ...

Business Overview - The company is a provider of innovative blood purification products, specializing in the research, development, production, and sales of blood perfusion-related products [3] - Products include single-use blood perfusion devices, single-use plasma bilirubin adsorbers, DNA immunoadsorption columns, and blood purification equipment, widely used in treating uremia, poisoning, severe liver diseases, autoimmune diseases, multiple organ failure, and ICU cases [3] - Blood purification technology is increasingly used as a third treatment option alongside surgery and medication [3] - The company's products are available in over 3,600 hospitals nationwide, with growing brand influence and rapid sales growth [3] Financial Performance - In 2017, the company achieved revenue of 718,491,131.27 yuan, a year-on-year increase of 32.16%, and net profit attributable to shareholders of 284,413,992.87 yuan, a year-on-year increase of 40.72% [3] - Key financial indicators for 2017 include a gross margin of 84.14%, net margin of 39.59%, operating cash flow of 304 million yuan, ROE of 22.21%, and debt-to-asset ratio of 18.26% [3] - In Q1 2018, revenue reached 207 million yuan, a year-on-year increase of 39.60%, and net profit attributable to shareholders was 89,976,900 yuan, a year-on-year increase of 50.89% [4] Core Competencies - A competitive talent team that shares in the company's growth [4] - Leading R&D capabilities and technological advantages [4] - Advanced marketing methods and a well-structured marketing organization [4] Future Development Plans - Focus on the blood purification field, deepen the domestic market, and expand overseas markets [4] - Develop new products to meet clinical needs and seek high-quality M&A targets to enhance product lines and technological capabilities [4] - Aim to build a comprehensive blood purification value chain and become a world-class high-tech medical technology enterprise group [4] Sales and Marketing - The company employs a buyout sales model through distributors, who then sell to hospital terminals [4] - Marketing strategies include demand stimulation, product promotion, and brand enhancement, supported by a self-built marketing team [4] - As of the end of 2017, the company had over 600 marketing personnel, with plans to expand the team in 2018 [5] Pricing and Technology - In 2017, the company reduced the price of HA130 from 680 yuan to 599 yuan, with no further price reduction plans [5] - The company holds relevant product patents and has mastered key technologies such as carrier synthesis, pore formation, activation, ligand grafting, and bio-film production [5] - The production process involves over 20 steps, each with strict control procedures to ensure product effectiveness, safety, and stability [5] Investor Communication - The company ensured transparent and fair communication with investors, adhering to information disclosure regulations and signing the required commitment letter [6]

Group 1: Impact of Policies on Products - The company's main product, disposable blood perfusion devices, is currently not included in the "centralized procurement" scope, and it is expected that it will not be included in the short term due to its low clinical usage and procurement volume [2][3] - The blood perfusion device does not meet the characteristics required for centralized procurement, such as high clinical usage, high procurement amounts, and maturity in clinical use [2][3] - If the product is included in centralized procurement in the future, sales are expected to increase significantly, enhancing the company's market share and profitability [3] Group 2: DRGs and Company Operations - The DRG (Diagnosis-Related Group) system is primarily applicable to acute inpatient cases and is not suitable for outpatient cases, which is relevant for the company's blood perfusion devices used in outpatient settings [3][4] - Most patients using the company's blood perfusion devices are outpatients, making them ineligible for DRG classification [3] Group 3: Business Development and Future Plans - The company is optimistic about its liver disease business, which has shown recovery in the second half of 2020 after the initial impact of COVID-19 [4] - Future development will focus on leveraging experience from the kidney disease sector to enhance the liver disease business [4] - The company plans to promote new products like dialysis machines and dialysis solutions through existing customer networks, emphasizing high-quality products and competitive pricing [4][5] Group 4: Long-term Strategy and Market Positioning - Over the next five years, the company aims to deepen its focus on kidney and liver disease, developing a comprehensive blood purification industry chain that includes medical devices, consumables, and services [5] - The company has initiated insurance products for kidney disease patients, enhancing customer loyalty and expanding its service offerings [5] - Future strategies include utilizing capital market resources and potential acquisitions to strengthen the company's unique blood purification industry chain [5]

Revenue and Profit - The company's revenue for Q3 2022 was ¥471,416,012.01, a decrease of 20.58% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥125,294,456.51, down 48.43% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥120,418,512.92, a decrease of 47.86% compared to the previous year[3] - The company's basic earnings per share for Q3 2022 was ¥0.17, down 43.33% year-on-year[3] - Total operating revenue for the current period reached ¥2,025,701,872.97, an increase of 13.7% compared to ¥1,781,805,266.01 in the previous period[18] - Operating profit for the current period was ¥1,021,591,465.64, slightly up from ¥1,013,971,252.26 in the previous period, reflecting a growth of 0.1%[19] - Net profit attributable to shareholders of the parent company was ¥873,450,879.06, compared to ¥863,085,578.68 in the previous period, indicating a growth of 1.4%[19] - Basic earnings per share increased to ¥1.10 from ¥1.08 in the previous period, while diluted earnings per share rose to ¥1.08 from ¥1.07[20] Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥5,144,905,239.58, an increase of 6.96% from the end of the previous year[3] - As of September 30, 2022, the total assets amounted to approximately CNY 5.14 billion, an increase from CNY 4.81 billion at the beginning of the year[15] - The total liabilities as of September 30, 2022, were approximately CNY 1.53 billion, compared to CNY 1.43 billion at the beginning of the year, indicating an increase of about 7.7%[16] - The company's equity attributable to shareholders rose to approximately CNY 3.59 billion from CNY 3.36 billion, marking an increase of about 6.9%[17] Cash Flow - The cash flow from operating activities for the year-to-date was ¥525,086,171.92, a decrease of 21.17% compared to the previous year[3] - Cash flow from operating activities generated a net amount of ¥525,086,171.92, down from ¥666,139,337.01 in the previous period, a decrease of 21.2%[21] - Cash inflow from investment activities totaled ¥2,113,400,711.80, compared to ¥2,330,043,064.21 in the previous period, reflecting a decrease of 9.3%[21] - The net cash flow from investing activities was -254,490,340.21 CNY, an improvement from -1,329,117,858.58 CNY in the previous year[22] - Total cash inflow from financing activities was 179,546,337.73 CNY, down from 1,192,629,344.86 CNY year-over-year[22] - The net cash flow from financing activities was -545,642,142.51 CNY, contrasting with a positive flow of 371,088,002.33 CNY in the previous year[22] - The cash and cash equivalents at the end of the period totaled 2,040,617,963.33 CNY, an increase from 1,278,225,616.54 CNY year-over-year[22] - The net decrease in cash and cash equivalents was -273,801,552.29 CNY, slightly better than -291,823,998.55 CNY in the previous year[22] Expenses and Costs - Research and development expenses increased by 68.86% year-on-year, totaling ¥162,284,135.93[8] - Total operating costs for the current period were ¥1,065,873,628.42, up from ¥821,488,233.10, representing a growth of 29.8%[18] - The company reported a tax expense of ¥146,865,226.90, slightly up from ¥146,513,524.66 in the previous period[19] Shareholder Information - The total number of ordinary shareholders reached 49,514, with the largest shareholder holding 43.97% of the shares[11] - The company’s largest shareholder, Dong Fan, holds 355,131,867 shares, representing a significant portion of the total equity[11] Inventory and Prepayments - The company reported a significant increase in inventory, which rose by 59.55% due to preparations for annual sales growth[6] - The inventory increased to approximately CNY 313.59 million from CNY 196.55 million, reflecting a growth of about 59.6%[15] - The company has seen a 101.71% increase in prepayments, primarily due to increased procurement prepayments[6] Other Financial Metrics - The weighted average return on equity was 3.62%, down 3.68% from the previous year[3] - The company received a VAT refund of approximately CNY 10.84 million, a significant increase of 3001.52% compared to the same period last year[9] - Cash paid for purchasing goods and services decreased by 30.76% to CNY 72.69 million, primarily due to a reduction in government subsidies received[9] - Cash paid to employees increased by 60.31% to CNY 478.19 million, attributed to an increase in employee count and average salary[9] - Total cash outflow from operating activities rose by 34.10% to CNY 1.72 billion, driven by increased procurement costs and employee compensation[9] - Cash inflow from financing activities decreased by 84.95% to CNY 179.55 million, mainly due to the absence of convertible bond issuance this year[10] - The company paid dividends amounting to CNY 720 million, reflecting a 35.59% increase compared to the previous year[10] Stock Options - The company has 243,016 stock options available for exercise in 2022, with 226,877 options exercised during the reporting period, leaving 16,138 options unexercised[14] Audit Status - The third quarter report was not audited, which may affect the perception of financial reliability[23]